Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
前收盘价
US$27.69
−US$0.11 · -0.40%
盘中时间采用ET。市场数据可能有所延迟。
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
日内区间
当前US$27.69
52周区间
当前US$27.69
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
85
深度低估
情绪
50
多空交织
风险
30
中等风险
动量
92
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
日内区间
当前US$27.69
52周区间
当前US$27.69
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 7377.6万 USD | 6400万 USD | 5471.6万 USD | 4806.7万 USD | 4165.9万 USD |
| 销货成本 | 1583.3万 USD | 1402.9万 USD | 1299万 USD | 1154.8万 USD | 1021.7万 USD |
| 毛利 | 5794.3万 USD | 4997.1万 USD | 4172.6万 USD | 3651.9万 USD | 3144.2万 USD |
| 研究与开发 | 131.4万 USD | 99.6万 USD | 65.6万 USD | 91.6万 USD | 135.6万 USD |
| 销售、一般及管理费用 | 4274.8万 USD | 3910.3万 USD | 3448.9万 USD | 3159.5万 USD | 2711.4万 USD |
| 营业费用 | 4406.2万 USD | 4009.9万 USD | 3514.5万 USD | 3251.1万 USD | 2847万 USD |
| 利息收入 | 47.9万 USD | 62.4万 USD | 45.5万 USD | 7.8万 USD | 2.5万 USD |
| 折旧和摊销 | 107.6万 USD | 117.2万 USD | 84.1万 USD | 61.3万 USD | 62.8万 USD |
| 营业利润 | 1388.1万 USD | 987.2万 USD | 658.1万 USD | 400.8万 USD | 297.2万 USD |
| 净利润 | 1130.1万 USD | 753.7万 USD | 515万 USD | 316.6万 USD | 230.5万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$48.50
上涨空间 75.15%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI551.39万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM485.11万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF228.36万0.00%954亿 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS204.09万0.01%338.69亿 USD0.31%US$78.35+0.32%
iShares Russell 2000 Growth ETFIWO173.68万0.01%139.17亿 USD0.24%US$356.78+0.94%
Fidelity Small-Mid Multifactor ETFFSMD143.21万0.06%24.9亿 USD0.15%US$49.96+0.48%
Vanguard Russell 2000 ETFVTWO106.87万0.01%180亿 USD0.06%US$112.66+0.50%
U.S. Micro Cap Portfolio ETFDFMC82.78万0.01%75.58亿 USD0.43%US$57.813+0.20%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
iShares Russell 2000 Growth ETFIWO
Fidelity Small-Mid Multifactor ETFFSMD
Vanguard Russell 2000 ETFVTWO
U.S. Micro Cap Portfolio ETFDFMCAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。